17/05/2023 ESTEVE REPORTS SIGNIFICANT GROWTH IN 2022 AND CONTINUES TO ADVANCE TOWARDS ITS VISION OF BECOMING AN INTERNATIONAL SPECIALTY PHARMA COMPANY Read more
26/05/2022 ESTEVE REINFORCES ITS COMMITMENT TO SUSTAINABILITY IN ALL THREE DIMENSIONS: SOCIAL, ENVIRONMENTAL AND ECONOMIC Read more
18/10/2021 ESTEVE ANNOUNCES FDA APPROVAL OF A NOVEL CO-CRYSTAL FORM OF CELECOXIB AND TRAMADOL FOR THE MANAGEMENT OF ACUTE PAIN Read more
Press Contact For more information please contact us: Irene Simón Global External Communications & CSR + 34 93 446 60 00isimon@esteve.com